Dr. Niharika Reddy Mallepally, MD, MPH

Dr. Mallepally practices at UCLA Health North Hollywood Digestive Diseases in North Hollywood, California.

Dr. Mallepally's NPI, 1679001333, was assigned on May 25, 2017. Dr. Mallepally graduated from Emory School of Medicine in 2016. Dr. Mallepally holds California license A170318.

Dr. Mallepally's primary practice is UCLA Health North Hollywood Digestive Diseases, at 4343 Lankershim Blvd, North Hollywood, CA 91602. The practice phone is (310) 301-8732.

Dr. Mallepally's primary practice is UCLA Health North Hollywood Digestive Diseases in North Hollywood, California. Dr. Mallepally is also affiliated with UCLA West Valley Medical Center. The medical group on file is UCLA Medical Group. Dmand AI also links Dr. Mallepally to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mallepally practices, 4 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Mallepally's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dr. Mallepally is board certified in gastroenterology by the American Board of Internal Medicine. Dr. Mallepally is licensed in California.

Dmand AI lists acid reflux among the conditions Dr. Mallepally treats.

CMS data shows 150 Medicare services from Dr. Mallepally across 5 procedure codes in 2024, for 135 Medicare patients. Medicare paid $19,057 for them.

CMS counts 135 Medicare patients who saw Dr. Mallepally in 2024. The largest group is 65 to 74, with 79 patients. 75% of them have high cholesterol, and 70% have high blood pressure. 30% are also on Medicaid. Their average risk score is 1.76, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mallepally's median patient age at 49, with 59% women.

In 2024, Dr. Mallepally wrote 233 Medicare Part D claims for 128 patients. 82% of them were for generic drugs. CMS names the drug for 143 of them, across 6 drugs with 11 or more claims each, at $4,192 in total drug cost. In 2023, CMS named 25 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Mallepally for performance year 2024, reported as part of a group. Dr. Mallepally accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mallepally as offering telehealth. CMS counts 39 procedures of colonoscopy by Dr. Mallepally, more than 58% of the clinicians it reports for that procedure.

Dmand AI links 15 papers to Dr. Mallepally, published from 2019 to 2025. 2019 was the busiest year, with 3. The most frequent topics are Adenocarcinoma, Helicobacter Infections and Helicobacter pylori. Dr. Mallepally has published most often in Dig Dis Sci. Dr. Mallepally's most frequent co-authors are Hashem Beshir El-Serag, MD, MPH, Mimi Chang Tan, MD, MPH and Yinghong Wang, MD, PhD.

CMS Open Payments shows 73 general payments to Dr. Mallepally from 10 drug and device companies from 2022 to 2025. Food and beverage make up the largest share, 100% of the total. Abbvie Inc. paid the most, $1,075.

Dr. Mallepally graduated from Emory School of Medicine in 2016.

Dr. Mallepally is in network with 14 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.